Patient-Reported Outcomes in Psoriatic Arthritis

Rheumatic Disease Clinics of North America

Volumn 42, Issue 2, 2016, Pages 265-283

  Orbai, Ana Maria ^a   Ogdie, Alexis ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Composite measures; Outcome measure; Patient reported outcome; Psoriatic arthritis

Indexed keywords

BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; COMPOSITE PSORIATIC DISEASE ACTIVITY INDEX; CONSTRUCT VALIDITY; CONTENT VALIDITY; CRITERION RELATED VALIDITY; DERMATOLOGY LIFE QUALITY INDEX; DISABILITIES OF THE ARM, SHOULDER AND HAND (SCORE); DISEASE ACTIVITY; DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS; DISEASE ACTIVITY SCORE; EUROPEAN QUALITY OF LIFE INDEX 5 DIMENSIONS; FATIGUE; FUNCTIONAL ASSESSMENT CHRONIC ILLNESS THERAPY FATIGUE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERNAL CONSISTENCY; MEASUREMENT ERROR; OUTCOME ASSESSMENT; PAIN; PATIENT REPORTED OUTCOME; PRIORITY JOURNAL; PRODUCTIVITY; PSA QUALITY OF LIFE INDEX; PSORIASIS SYMPTOM INVENTORY; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE; PSORIATIC ARTHRITIS IMPACT OF DISEASE; PSORIATIC ARTHRITIS RESPONSE CRITERIA; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; REVIEW; SCORING SYSTEM; SHORT FORM 36; SKIN DISEASE; SLEEP DISORDER; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; WORK PRODUCTIVITY SURVEY; ARTHRALGIA; ARTHRITIS, PSORIATIC; CLINICAL TRIAL (TOPIC); COMPLICATION; DAILY LIFE ACTIVITY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PATIENT-REPORTED OUTCOME; PRURITUS; QUESTIONNAIRE;

ACTIVITIES OF DAILY LIVING; ARTHRALGIA; ARTHRITIS, PSORIATIC; CLINICAL TRIALS AS TOPIC; FATIGUE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PATIENT REPORTED OUTCOME MEASURES; PRURITUS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84961124422     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2016.01.002     Document Type: Review

References (95)

1. Taylor W.J., Mease P.J., Adebajo A., et al. Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol 2010, 37(9):1885-1891.
2. Gladman D.D., Mease P.J., Strand V., et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007, 34(5):1167-1170.
3. Tillett W., Adebajo A., Brooke M., et al. Patient involvement in outcome measures for psoriatic arthritis. Curr Rheumatol Rep 2014, 16(5):418.
4. Gossec L., de Wit M., Kiltz U., et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014, 73(6):1012-1019.
5. Mease P.J. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011, 63(Suppl 11):S64-S85.
6. Cauli A., Gladman D.D., Mathieu A., et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011, 38(5):898-903.
7. Pincus T., Skummer P.T., Grisanti M.T., et al. MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter. Bull NYU Hosp Jt Dis 2012, 70(3):177-186.
8. Guyatt G.H., Feeny D.H., Patrick D.L. Measuring health-related quality of life. Ann Intern Med 1993, 118(8):622-629.
9. Mossey J.M., Shapiro E. Self-rated health: a predictor of mortality among the elderly. Am J Public Health 1982, 72(8):800-808.
10. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31(3):247-263.
11. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
12. Hays R.D., Morales L.S. The RAND-36 measure of health-related quality of life. Ann Med 2001, 33(5):350-357.
13. Leung Y.Y., Zhu T.Y., Tam L.S., et al. Minimal important difference and responsiveness to change of the SF-36 in patients with psoriatic arthritis receiving tumor necrosis factor-alpha blockers. J Rheumatol 2011, 38(9):2077-2079.
14. Kosinski M., Zhao S.Z., Dedhiya S., et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000, 43(7):1478-1487.
15. Saad A.A., Ashcroft D.M., Watson K.D., et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken) 2010, 62(3):345-353.
16. Strand V., Sharp V., Koenig A.S., et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis 2012, 71(7):1143-1150.
17. Ahmad M.A., Xypnitos F.N., Giannoudis P.V. Measuring hip outcomes: common scales and checklists. Injury 2011, 42(3):259-264.
18. Leung Y.Y., Png M.E., Wee H.L., et al. Comparison of EuroQol-5D and short form-6D utility scores in multiethnic Asian patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 2013, 40(6):859-865.
19. Gignac M.A., Cao X., McAlpine J., et al. Measures of disability: arthritis impact measurement scales 2 (AIMS2), Arthritis Impact Measurement Scales 2-Short Form (AIMS2-SF), The Organization for Economic Cooperation and Development (OECD) Long-Term Disability (LTD) Questionnaire, EQ-5D, World Health Organization Disability Assessment Schedule II (WHODASII), Late-Life Function and Disability Instrument (LLFDI), and Late-Life Function and Disability Instrument-Abbreviated Version (LLFDI-Abbreviated). Arthritis Care Res 2011, 63(Suppl 11):S308-S324.
20. Husted J., Gladman D.D., Farewell V.T., et al. Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic arthritis. J Rheumatol 1996, 23(6):1015-1019.
21. Husted J., Gladman D.D., Long J.A., et al. Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol 1996, 23(11):1932-1937.
22. Long J.A., Husted J.A., Gladman D.D., et al. The relationship between patient satisfaction with health and clinical measures of function and disease status in patients with psoriatic arthritis. J Rheumatol 2000, 27(4):958-966.
23. McKenna S.P., Doward L.C., Whalley D., et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004, 63(2):162-169.
24. Brodszky V., Pentek M., Balint P.V., et al. Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scand J Rheumatol 2010, 39(4):303-309.
25. Billing E., McKenna S.P., Staun M., et al. Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden. Scand J Rheumatol 2010, 39(3):223-228.
26. Wink F., Arends S., McKenna S.P., et al. Validity and reliability of the Dutch adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire. PLoS One 2013, 8(2):e55912.
27. Doward L.C., Spoorenberg A., Cook S.A., et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003, 62(1):20-26.
28. Leung Y.Y., Tam L.S., Kun E.W., et al. Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. J Rheumatol 2008, 35(8):1613-1621.
29. Husted J.A., Gladman D.D., Cook R.J., et al. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998, 25(11):2146-2155.
30. Husted J.A., Gladman D.D., Farewell V.T., et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24(3):511-517.
31. Taal E., Rasker J.J., Riemsma R.P. Sensitivity to change of AIMS2 and AIMS2-SF components in comparison to M-HAQ and VAS-pain. Ann Rheum Dis 2004, 63(12):1655-1658.
32. Chaudhry S.R., Thavaneswaran A., Chandran V., et al. Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis. Rheumatology (Oxford) 2013, 52(4):705-711.
33. Eder L., Thavaneswaran A., Chandran V., et al. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken) 2015, 67(2):264-272.
34. Husted J.A., Tom B.D., Farewell V.T., et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time?. Arthritis Rheum 2007, 56(3):840-849.
35. Castrejon I., Bergman M.J., Pincus T. MDHAQ/RAPID3 to recognize improvement over 2 months in usual care of patients with osteoarthritis, systemic lupus erythematosus, spondyloarthropathy, and gout, as well as rheumatoid arthritis. J Clin Rheumatol 2013, 19(4):169-174.
36. Pincus T., Swearingen C.J., Bergman M., et al. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 2008, 35(11):2136-2147.
37. Pincus T., Furer V., Keystone E., et al. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res 2011, 63(8):1142-1149.
38. Castrejon I., Dougados M., Combe B., et al. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol 2013, 40(4):386-393.
39. Danve A., Reddy A., Vakil-Gilani K., et al. Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis. Clin Rheumatol 2015, 34(1):117-124.
40. Castrejon I., Yazici Y., Pincus T. Patient self-report RADAI (Rheumatoid Arthritis Disease Activity Index) joint counts on an MDHAQ (Multidimensional Health Assessment Questionnaire) in usual care of consecutive patients with rheumatic diseases other than rheumatoid arthritis. Arthritis Care Res 2013, 65(2):288-293.
41. Leeb B.F., Haindl P.M., Brezinschek H.P., et al. Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA). BMC Musculoskelet Disord 2015, 16:73.
42. Garrett S., Jenkinson T., Kennedy L.G., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994, 21(12):2286-2291.
43. Taylor W.J., Harrison A.A. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?. Arthritis Rheum 2004, 51(3):311-315.
44. Fernandez-Sueiro J.L., Willisch A., Pertega-Diaz S., et al. Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res (Hoboken) 2010, 62(1):78-85.
45. Eder L., Chandran V., Shen H., et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. Ann Rheum Dis 2010, 69(12):2160-2164.
46. Fries J.F., Spitz P., Kraines R.G., et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23(2):137-145.
47. Wolfe F., Kleinheksel S.M., Cathey M.A., et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988, 15(10):1480-1488.
48. Navarro-Compan V., Landewe R., Provan S.A., et al. Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. Rheumatology (Oxford) 2015, 54(1):83-90.
49. Ward M.M., Guthrie L.C., Alba M.I. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis 2015, 74(9):1691-1696.
50. Mease P.J., Woolley J.M., Bitman B., et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 2011, 38(11):2461-2465.
51. Taylor W.J., McPherson K.M. Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 2007, 57(5):723-729.
52. Fries J.F., Bruce B., Rose M. Comparison of the health assessment questionnaire disability index and the short form 36 physical functioning subscale using Rasch analysis: comment on the article by Taylor and McPherson. Arthritis Rheum 2008, 59(4):598-599. [author reply: 9].
53. Calin A., Garrett S., Whitelock H., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 1994, 21(12):2281-2285.
54. Lee S., Mendelsohn A., Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 2010, 35(12):680-689.
55. Navsarikar A., Gladman D.D., Husted J.A., et al. Validity assessment of the disabilities of arm, shoulder, and hand questionnaire (DASH) for patients with psoriatic arthritis. J Rheumatol 1999, 26(10):2191-2194.
56. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19(3):210-216.
57. Nichol M.B., Margolies J.E., Lippa E., et al. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996, 10(6):644-653.
58. Mattei P.L., Corey K.C., Kimball A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014, 28(3):333-337.
59. Lundberg L., Johannesson M., Silverdahl M., et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000, 80(6):430-434.
60. Bushnell D.M., Martin M.L., Scanlon M., et al. Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory. Qual Life Res 2014, 23(3):897-906.
61. Martin M.L., McCarrier K.P., Chiou C.F., et al. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat 2013, 24(4):255-260.
62. Bushnell D.M., Martin M.L., McCarrier K., et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat 2013, 24(5):356-360.
63. Wilson H.D., Mutebi A., Revicki D.A., et al. Reliability and validity of the psoriasis symptom inventory in patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 2015, 67(12):1750-1756.
64. Naegeli A.N., Flood E., Tucker J., et al. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015, 54(6):715-722.
65. Yellen S.B., Cella D.F., Webster K., et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997, 13(2):63-74.
66. Chandran V., Bhella S., Schentag C., et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007, 66(7):936-939.
67. Cella D., Yount S., Sorensen M., et al. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005, 32(5):811-819.
68. Hewlett S., Dures E., Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res 2011, 63(Suppl 11):S263-S286.
69. Tillett W., de-Vries C., McHugh N.J. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford) 2012, 51(2):275-283.
70. Kristensen L.E., Englund M., Neovius M., et al. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis 2013, 72(10):1675-1679.
71. Osterhaus J.T., Purcaru O., Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 2009, 11(3):R73.
72. Osterhaus J.T., Purcaru O. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis. Arthritis Res Ther 2014, 16(4):R140.
73. Leung Y.Y., Ho K.W., Zhu T.Y., et al. Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. Rheumatology (Oxford) 2010, 49(8):1495-1501.
74. Husted J.A., Cook R.J., Farewell V.T., et al. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000, 53(5):459-468.
75. Kwok T., Pope J.E. Minimally important difference for patient-reported outcomes in psoriatic arthritis: health assessment questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 2010, 37(5):1024-1028.
76. Callis Duffin K., Wong B., Horn E.J., et al. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol 2009, 60(4):604-608.
77. Strober B.E., Sobell J.M., Duffin K.C., et al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol 2012, 167(6):1374-1381.
78. Williams D.A., Arnold L.M. Measures of fibromyalgia: fibromyalgia impact questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res 2011, 63(Suppl 11):S86-S97.
79. Gladman D.D., Tom B.D., Mease P.J., et al. Informing response criteria for psoriatic arthritis (PsA). II: further considerations and a proposal-the PsA joint activity index. J Rheumatol 2010, 37(12):2559-2565.
80. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38(6):727-735.
81. Prevoo M.L., van 't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38(1):44-48.
82. Nell-Duxneuner V.P., Stamm T.A., Machold K.P., et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010, 69(3):546-549.
83. Schoels M., Aletaha D., Funovits J., et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010, 69(8):1441-1447.
84. Helliwell P.S., FitzGerald O., Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014, 41(6):1212-1217.
85. Schoels M.M., Aletaha D., Alasti F., et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2015, [Epub ahead of print].
86. Mumtaz A., Gallagher P., Kirby B., et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011, 70(2):272-277.
87. Helliwell P.S., FitzGerald O., Fransen J., et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013, 72(6):986-991.
88. Helliwell P.S., Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res 2014, 66(5):749-756.
89. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010, 69(1):48-53.
90. Clegg D.O., Reda D.J., Mejias E., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs cooperative study. Arthritis Rheum 1996, 39(12):2013-2020.
91. Fransen J., Antoni C., Mease P.J., et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006, 65(10):1373-1378.
92. Mease P.J., Fleischmann R., Deodhar A.A., et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014, 73(1):48-55.
93. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356(9227):385-390.
94. Gladman D.D., Tom B.D., Mease P.J., et al. Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 2010, 37(9):1892-1897.
95. Gladman DD1; ACCLAIM Study Investigators, Sampalis J.S., et al. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010, 37(9):1898-1906.